- Home
- MKSI vs ROIV Comparison
MKSI vs ROIV Comparison
Compare MKSI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKSI
- ROIV
- Stock Information
- Founded
- MKSI 1961
- ROIV 2014
- Country
- MKSI United States
- ROIV United Kingdom
- Employees
- MKSI N/A
- ROIV N/A
- Industry
- MKSI Industrial Machinery/Components
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- MKSI Industrials
- ROIV Health Care
- Exchange
- MKSI Nasdaq
- ROIV Nasdaq
- Market Cap
- MKSI N/A
- ROIV 8.4B
- IPO Year
- MKSI 1999
- ROIV N/A
- Fundamental
- Price
- MKSI $111.11
- ROIV $10.94
- Analyst Decision
- MKSI Strong Buy
- ROIV Strong Buy
- Analyst Count
- MKSI 11
- ROIV 8
- Target Price
- MKSI $143.00
- ROIV $17.93
- AVG Volume (30 Days)
- MKSI 701.3K
- ROIV 5.3M
- Earning Date
- MKSI 02-05-2025
- ROIV 02-11-2025
- Dividend Yield
- MKSI 0.79%
- ROIV N/A
- EPS Growth
- MKSI N/A
- ROIV N/A
- EPS
- MKSI 0.45
- ROIV 5.89
- Revenue
- MKSI $3,544,000,000.00
- ROIV $129,128,999.00
- Revenue This Year
- MKSI $0.41
- ROIV $15.98
- Revenue Next Year
- MKSI $8.06
- ROIV N/A
- P/E Ratio
- MKSI $245.43
- ROIV $1.86
- Revenue Growth
- MKSI N/A
- ROIV 145.68
- 52 Week Low
- MKSI $97.54
- ROIV $9.69
- 52 Week High
- MKSI $147.40
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- MKSI 53.46
- ROIV 38.75
- Support Level
- MKSI $105.34
- ROIV $10.42
- Resistance Level
- MKSI $116.63
- ROIV $11.82
- Average True Range (ATR)
- MKSI 3.14
- ROIV 0.35
- MACD
- MKSI 0.50
- ROIV -0.11
- Stochastic Oscillator
- MKSI 61.53
- ROIV 29.21
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.